This document provides information about the 20th Annual Superbugs & Superdrugs conference on tackling antimicrobial resistance that will take place on March 19-21, 2018 in London. The conference will feature presentations on funding and regulatory approaches for new antibiotic development, strategies to combat resistant pathogens, and research on novel antibiotic candidates and alternatives. A half-day workshop on March 21st will provide an overview of using animal models in pre-clinical drug development.
SMi Group's Superbugs and Superdrugs USA 2018Dale Butler
This document provides information on the 3rd annual Superbugs & Superdrugs USA conference taking place November 12-13, 2018 in Iselin, New Jersey. Anthony Simon Lynch and William Weiss will chair the event. Featured speakers will discuss topics such as pathogen-focused drug development, antibiotic resistance, novel modes of action to overcome resistance, and new anti-fungal developments. Participants will learn about funding opportunities, rapid diagnostic methods, and case studies. Two half-day workshops on November 14 will focus on rapid diagnostics for drug resistance and challenges of commercializing new antibiotics. SCYNEXIS, Inc. is sponsoring the conference.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
This document provides information about the 4th Annual Conference on Cancer Vaccines to be held on September 16-17, 2015 in London. Professor Farzin Farzaneh of Kings College London will chair the conference. Key topics to be addressed include tumour genetic heterogeneity in immunotherapy, combination therapies to advance immune-oncology vaccines, and developments in targeted and personalized cancer treatments. There will be presentations from industry and academic leaders in the field.
Lighting Rockets at the UChicago Microbiome LaunchpadLaura Berry
Presented at the 5th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit:
www.global-engage.com
With the recent gift of $100 million, the Duchossois Family Institute was established, providing UChicago with the resources to develop models for translating microbiome research. Matt Martin discusses their plans for expanding the support provided to faculty and the mechanisms for launching their startups and technologies.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
SMi Group's Superbugs and Superdrugs USA 2018Dale Butler
This document provides information on the 3rd annual Superbugs & Superdrugs USA conference taking place November 12-13, 2018 in Iselin, New Jersey. Anthony Simon Lynch and William Weiss will chair the event. Featured speakers will discuss topics such as pathogen-focused drug development, antibiotic resistance, novel modes of action to overcome resistance, and new anti-fungal developments. Participants will learn about funding opportunities, rapid diagnostic methods, and case studies. Two half-day workshops on November 14 will focus on rapid diagnostics for drug resistance and challenges of commercializing new antibiotics. SCYNEXIS, Inc. is sponsoring the conference.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
This document provides information about the 4th Annual Conference on Cancer Vaccines to be held on September 16-17, 2015 in London. Professor Farzin Farzaneh of Kings College London will chair the conference. Key topics to be addressed include tumour genetic heterogeneity in immunotherapy, combination therapies to advance immune-oncology vaccines, and developments in targeted and personalized cancer treatments. There will be presentations from industry and academic leaders in the field.
Lighting Rockets at the UChicago Microbiome LaunchpadLaura Berry
Presented at the 5th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit:
www.global-engage.com
With the recent gift of $100 million, the Duchossois Family Institute was established, providing UChicago with the resources to develop models for translating microbiome research. Matt Martin discusses their plans for expanding the support provided to faculty and the mechanisms for launching their startups and technologies.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
This document summarizes PCT's vision and history as a leader in cell therapy manufacturing. PCT aims to make transformative cell-based therapies accessible to all through providing high-quality and scalable manufacturing services. Over 30 years, PCT has gained unprecedented expertise manufacturing over 20 cell therapy products and treating over 6,000 patients. PCT partners with companies from start-ups to large pharmaceutical companies, and aims to guide clients through the entire development and manufacturing process.
Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Antibiotic Guardian London Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
- Neusentis is a regenerative medicine subsidiary of Pfizer focused on developing cell-based therapies.
- Their portfolio includes collaborations on stem cell-derived retinal pigment epithelial (RPE) cells to treat macular degeneration, and allogenic adult multipotent stem cells to treat inflammatory bowel disease.
- Major challenges for developing and commercializing cell therapies include cell biology and manufacturing complexities, rigorous clinical trial design and supply logistics, and demonstrating a clear business case for pricing and reimbursement.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
Webinar: Re-imagining vaccine manufacturing to address global health challengesMilliporeSigma
Participate in the interactive on demand webinar: http://bit.ly/ReimaginingVaccinesWebinar
In this webinar, you will learn:
- The evolution of vaccine production in response to pandemics and outbreaks
- Key considerations and perspectives on how vaccine processing and facilities could change to address future global health challenges
Sponsor Day on animal feeding: Animal production without antibiotics. Where a...Irta
This document discusses alternatives to antibiotic use in animal production. It begins by reviewing the history of antibiotic resistance, current antibiotic usage levels in Europe, and reasons antibiotics are commonly used. It then describes initiatives like the European Innovation Partnership to promote innovation. One focus group examined alternatives to antibiotics under three headings: attitudes and information, general animal health and welfare improvements, and specific alternatives. Recommendations included benchmarking systems, economic evaluations, biosecurity improvements, vaccination, and zinc or prebiotic supplementation.
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals can
SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
SMi Group's Superbugs and Superdrugs USA 2016Dale Butler
This document provides information about the "Superbugs & Superdrugs USA" conference happening from November 14-16, 2016. It advertises the opportunity to register for the conference at discounted rates by certain deadlines. The conference will focus on developing new drugs to combat antibiotic resistance and will feature expert speakers from organizations like the WHO, BARDA, NIH, Pfizer and others. An interactive workshop on animal models in pre-clinical drug development will also be held.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
This document summarizes PCT's vision and history as a leader in cell therapy manufacturing. PCT aims to make transformative cell-based therapies accessible to all through providing high-quality and scalable manufacturing services. Over 30 years, PCT has gained unprecedented expertise manufacturing over 20 cell therapy products and treating over 6,000 patients. PCT partners with companies from start-ups to large pharmaceutical companies, and aims to guide clients through the entire development and manufacturing process.
Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Antibiotic Guardian London Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
- Neusentis is a regenerative medicine subsidiary of Pfizer focused on developing cell-based therapies.
- Their portfolio includes collaborations on stem cell-derived retinal pigment epithelial (RPE) cells to treat macular degeneration, and allogenic adult multipotent stem cells to treat inflammatory bowel disease.
- Major challenges for developing and commercializing cell therapies include cell biology and manufacturing complexities, rigorous clinical trial design and supply logistics, and demonstrating a clear business case for pricing and reimbursement.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
Webinar: Re-imagining vaccine manufacturing to address global health challengesMilliporeSigma
Participate in the interactive on demand webinar: http://bit.ly/ReimaginingVaccinesWebinar
In this webinar, you will learn:
- The evolution of vaccine production in response to pandemics and outbreaks
- Key considerations and perspectives on how vaccine processing and facilities could change to address future global health challenges
Sponsor Day on animal feeding: Animal production without antibiotics. Where a...Irta
This document discusses alternatives to antibiotic use in animal production. It begins by reviewing the history of antibiotic resistance, current antibiotic usage levels in Europe, and reasons antibiotics are commonly used. It then describes initiatives like the European Innovation Partnership to promote innovation. One focus group examined alternatives to antibiotics under three headings: attitudes and information, general animal health and welfare improvements, and specific alternatives. Recommendations included benchmarking systems, economic evaluations, biosecurity improvements, vaccination, and zinc or prebiotic supplementation.
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals can
SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
SMi Group's Superbugs and Superdrugs USA 2016Dale Butler
This document provides information about the "Superbugs & Superdrugs USA" conference happening from November 14-16, 2016. It advertises the opportunity to register for the conference at discounted rates by certain deadlines. The conference will focus on developing new drugs to combat antibiotic resistance and will feature expert speakers from organizations like the WHO, BARDA, NIH, Pfizer and others. An interactive workshop on animal models in pre-clinical drug development will also be held.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
Healthcare-associated infections are a major public health problem worldwide and a leading cause of death in hospitals. Antimicrobial resistance poses a serious threat as many antibiotics are becoming ineffective. Disinfection and sanitization are important first lines of defense against disease-causing microbes. However, research and development of new and effective disinfectants has been limited by a lack of funding and public perception of disinfectants as non-essential. Increased investment in disinfectant research and ensuring proper use and training are needed to address the growing risks of antibiotic resistance.
This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
This document provides information about an upcoming conference on immunogenicity to be held June 13-14, 2016 in London. It includes an overview of the conference sessions and speakers. The sessions will cover topics such as approaches to standardizing drug level and anti-drug antibody assays, unwanted immunogenicity, integrating immunogenicity risk data, immunogenicity of biologics and biosimilars, and the role of aggregation in immunogenicity. There will also be two half-day post-conference workshops on June 15 on standardizing assays for biotherapeutics and unwanted immunogenicity from the bench to the bedside. The conference is aimed at accelerating development and approval of next generation biotherapeutics by adopting
SMi’s 3rd annual conference
Immunogenicity
13th and 14th June 2016, Holiday In Kensington Forum, London, UK.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
For further information or to register please visit the event website www.immuno.co.uk or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
The document discusses the key role of diagnostics in addressing the challenge of antimicrobial resistance (AMR). It makes three key points:
1) AMR is a major threat as many infections are becoming increasingly difficult to treat due to drug-resistant bacteria. Without effective antibiotics, common infections and surgeries could become life-threatening.
2) Diagnostics are critical to appropriate antibiotic use by enabling rapid and precise diagnosis of whether a bacterial or viral infection is present and, if bacterial, determining the best antibiotic to use or avoid. This can help reduce unnecessary antibiotic prescribing.
3) The document outlines a vision for AMR diagnostics in the UK to ensure rapid diagnostic technologies are universally available to guide antibiotic
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Immunotherapy Europe - The Perfect Combination of Strategy and Innovation Michael Adeniya
Phacilitate's Immunotherapy Europe will bring leaders in the field together. big phama, biotech, payers, HTAs, regulators and investors. See what's being discussed at Europe's ONLY commercial meeting for Immunotherapy!
SMi Group's 7th annual Biosimilars Europe 2016 conferenceDale Butler
This document provides information about two pre-conference workshops for the 7th Annual Biosimilars Europe conference.
The first workshop focuses on maximizing intellectual property and regulatory rights related to biosimilars. It will cover topics like regulatory data protection, orphan drug exclusivity, supplementary protection certificates, and pediatric rewards. The workshop leaders are partners at Bristows LLP.
The second workshop examines how the payer environment for biosimilars is evolving. It will provide insight into pricing, reimbursement, and formulary access processes. Case studies will also be presented on successful biosimilar launches. The workshop leader is the director of RJW & Partners Ltd, a pricing and market
SMi will host the 7th Pharmaceutical Microbiology West Coast conference on June 8-9, 2017 in San Diego, USA. The conference will address current challenges in sterility assurance, environmental monitoring, and rapid microbial methods. Over the two days, experts from companies like GSK, Amgen, Janssen, and Takeda will discuss topics like environmental monitoring trends and data analysis, challenges in endotoxin testing and sterility assurance, case studies on contamination control, and the validation and use of rapid microbial methods. Workshops on the day before will cover technologies for monitoring contamination control and case studies, as well as microbial requirements for terminal sterilization.
SMi Group's Injectable Drug Delivery 2019 conferenceDale Butler
The document advertises the 2nd Annual Injectable Drug Delivery conference taking place May 14-16, 2019 in London. The conference will focus on innovations in injectable drug formulations and devices, with sessions on formulation development, device design, manufacturing, and regulatory issues. Speakers will discuss challenges and solutions for protein formulations, digital health technologies, long-acting injectables, pre-filled syringes and more. A pre-conference workshop on use-related risk analysis in product development will also be held. Attendees can register online or by phone.
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
World ADC Frankfurt 2015 - sample brochureWorld ADC
The World ADC Frankfurt meeting has been established with the simple mission of speeding up the development of more potent and safe antibody drug conjugates.
Learn not only how to make an ADC, but how to make a great one. With insights on numerous novel payload technologies, robust strategies for preclinical evaluation and emerging clinical data, there is no better opportunity to accelerate your research.
SMi Group's Pharmaceutical Microbiology West Coast 2020 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology West Coast conference happening June 17-19, 2020 in San Diego. It outlines the chairs, speakers, highlights and agenda for the event. The conference will focus on novel approaches and best practices for tackling current industry contamination control challenges, and will include sessions on contamination control, guidance and regulations, detection and identification methods, and supporting pharmaceutical facilities and novel therapeutics. There will also be an optional pre-conference workshop on data integrity in environmental monitoring.
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
This document provides an agenda for the 5th annual Pre-Filled Syringes West Coast conference taking place June 15-17, 2020 in San Diego, CA. The conference will focus on innovations in device design and technology, advances in human factors engineering, combination product regulatory insights, and design controls and risk management. It will feature presentations from industry leaders at companies like Genentech and AstraZeneca as well as regulators from the FDA. There will also be two post-conference workshops on June 17th focusing on navigating FDA requirements for connected devices and digital health, and post-market safety reporting for combination products.
SMi Group's Military Robotics and Autonomous Systems USA 2020 conferenceDale Butler
This document advertises the Military Robotics and Autonomous Systems USA conference happening on June 22-23, 2020 in Arlington, Virginia. Attendees can save $400 by registering by February 28, $200 by registering by March 31, and $100 by registering by April 30. The conference will discuss topics like US Army robotics programs, Australian Army robotics development, unmanned vehicle programs, robotics supporting warfighters' mobility and sustainability, and integrating robotics into ground formations. Speakers will include representatives from the US and Australian militaries as well as academics working on relevant research.
SMi Group's Future Soldier Technology USA 2020 conferenceDale Butler
The document announces the 2nd Annual Future Soldier Technology USA conference on June 8-10, 2020 in Arlington, Virginia. The conference will focus on modernizing equipment for dismounted soldiers and marines, and feature speakers from the US and other militaries involved in soldier technology programs. Over 150 attendees are expected to discuss initiatives like NGSW-AR/R/FC, ISSP, and manned-unmanned teaming to enhance soldier lethality, mobility, and situational awareness.
SMi Group's Military Space USA 2020 conferenceDale Butler
This document provides an agenda for the 2nd Annual Military Space USA Conference supporting the US military space enterprise. The conference will include presentations from senior leaders in the US Space Force, Air Force, and other allied militaries on topics such as space acquisition reform through SMC 2.0, training the future space warfighting force, and leveraging disruptive commercial space technologies. A separate focus day will explore experimental smallsat capabilities, export controls for space technologies, advanced propulsion concepts, using LEO mega-constellations for bandwidth, in-orbit manufacturing, and accelerating commercial innovation. The event aims to connect disruptors and innovators with government to integrate new technologies rapidly into military space operations.
This document summarizes a conference focused on helicopter technology for Central and Eastern Europe being held in Budapest, Hungary on May 20-21, 2020. It will feature keynote speeches from military leaders from Hungary, Slovakia, Romania, Germany, and Croatia on developments and modernization efforts of their national helicopter fleets. Technical experts from the US, UK, Netherlands, and Czech Republic will also present. Sessions will discuss regional cooperation and interoperability, training standards, and enhancing capabilities like search and rescue. The goal is focused discussion on challenges facing helicopter program managers and informal networking for participants.
This document provides information about an upcoming conference on future armoured vehicles in Central and Eastern Europe in 2020. It outlines early registration discounts that decrease over time, as well as special rates for military and government representatives. The document details benefits of attending the conference, including hearing updates from armed forces in the region. It lists speakers from various countries who will discuss topics like armoured vehicle programmes, enhancing capabilities, and ensuring interoperability. The agenda outlines presentations over two days covering issues like future infantry fighting vehicles, enhancing mechanization capabilities, and modernizing ground platforms. The document promotes sponsorship opportunities at the event.
SMi Group's Unmanned Maritime Systems 2020 conferenceDale Butler
This document provides information about the 4th Annual Unmanned Maritime Systems conference taking place on April 13-14, 2020 in London. It discusses key reasons to attend like hearing from naval officers on integrating unmanned assets and learning about updates on unmanned platforms, anti-submarine warfare, mine countermeasures, and technological innovation. The agenda outlines presentations and speakers from military organizations like the Royal Navy, US Navy, Spanish Navy, and NATO who will discuss topics like developing unmanned systems, accelerating unmanned technologies, and using unmanned systems for mine countermeasure operations.
SMi Group's Military PNT 2020 conferenceDale Butler
The document summarizes the agenda for the "Military PNT 2020" conference to be held on May 18-19 in London. The event highlights include briefings from the US DoD on GPS and NTS-3 programs, understanding requirements for operating in degraded PNT environments, and engaging with industry and military leaders. The agenda covers topics such as UK PNT strategies, warfighter PNT considerations, legal perspectives on PNT resilience, and GNSS interference case studies. Keynote speakers include representatives from the US Air Force, Lockheed Martin, UK MoD, DGA, NPL, and BHO Legal.
This document provides an agenda for the Defence Aviation Safety conference taking place on April 23-24, 2020 in London. The agenda includes keynote presentations and panels on topics related to ensuring safety across defence aviation programs and platforms. Speakers will represent organisations such as the UK Ministry of Defence, US Air Force, German Military Aviation Authority, and NATO. Presentation topics will cover safety priorities, certification processes, training, accident investigation and lessons learned. A closing panel on day two will discuss the challenges of ensuring military aviation safety and cyber resilience.
SMi Group's Pre-filled Syringes East Coast 2020 Dale Butler
This document announces an interactive workshop on combination product development taking place on April 29th, 2020 in Boston, USA. The workshop will consist of three sessions focused on key topics in combination product development: combination product development strategies, drug delivery device testing solutions, and human factors validation studies. Speakers will include experts from major pharmaceutical companies such as AstraZeneca, Eli Lilly, Biogen, and regulatory agencies. The workshop aims to provide attendees insights and strategies for navigating challenges in combination product development from concept to approval.
SMi Group's Air Mission Planning and Support 2020Dale Butler
The document announces an upcoming conference on "Maximising Air Power through the Development and Integration of Innovative Support Systems" to be held in London on April 21-22, 2020. The conference will examine developments in air mission planning and focus on data management, fifth generation integration, and multi-domain command and control. It will feature expert military speakers from countries like the UK, US, Canada, France, Hungary, and Belgium representing air forces, NATO, and DARPA to discuss challenges and solutions.
SMi Group's Military Robotics and Autonomous Systems 2020 Dale Butler
This document provides information about the 3rd Annual Military Robotics and Autonomous Systems conference taking place on April 1-2, 2020 in London. It outlines the key topics to be discussed including UK and international perspectives on robotic and autonomous systems programs and strategies. Speakers will address topics such as unmanned ground vehicle development, autonomy for military robotic systems, and manned-unmanned teaming. The conference will explore delivering quality robotic systems to enhance operational effectiveness and discuss technology demonstrations.
This document advertises the 6th Annual Future Soldier Technology conference taking place March 9-11, 2020 in London. The conference will focus on dismounted soldier and marine technology, discussing key areas like dismounted capability. Military, procurement, and research experts from around the world will present on their soldier programs, challenges, and successes. Attendees can learn the latest developments, network with key speakers and decision makers, and gather intelligence to inform their projects. The conference aims to allow information sharing on equipping soldiers to maintain an advantage against evolving adversaries.
This document provides information about the 5th Annual Defence Logistics Central & Eastern Europe conference taking place on March 3-4, 2020 in Budapest, Hungary. The summary includes:
- The conference will bring together senior military, government, and industry personnel from Central and Eastern Europe to discuss developments in defence logistics and increase cooperation in the region.
- Over the two days, there will be keynote briefings and panels on topics like modernizing logistics structures, interoperability, operational capabilities of country logistics divisions, and industry roles. Speakers will represent militaries like Hungary, Czech Republic, Poland, and industry sponsors.
- Attendees can benefit from networking opportunities and learning about log
The document announces Space Week, consisting of the Small Satellites Conference from April 27-28 and the Military Space Situational Awareness Conference from April 29-30 in London. It provides details on the conferences, including chairpersons, speakers from various space agencies, companies, and militaries, and topics to be discussed such as small satellites, space insurance, disruptive approaches to space, space data, and military space situational awareness. The document aims to invite colleagues to participate in Space Week to explore developments in small satellites and how to track and manage space assets.
SMi Group's AI in Drug Discovery 2020 conferenceDale Butler
This document provides information about an upcoming conference on AI in Drug Discovery taking place from March 16-17, 2020 in London, UK. It includes details about the program, speakers, registration fees and deadlines. The conference will explore how machine learning and AI are being applied across the drug discovery process, from compound design and virtual screening to toxicity prediction. There will be case studies presented from major pharmaceutical companies on their experience integrating AI. The document also advertises sponsorship opportunities for the event.
The document announces a conference on exploring the small satellite revolution and its impact on future space. It will be held on April 27-28, 2020 in London, UK and include a half-day post-conference workshop on April 29. The conference will discuss topics such as disruptive approaches to space, small satellite applications, space data and networking, insurance, and market trends and opportunities. It will feature expert speakers from organizations such as NASA, Surrey Satellite Technology, the Israeli Space Agency, US Air Force, and more. Attendees can learn about key small satellite programs and how these systems are transforming capabilities.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Thinking of getting a dog? Be aware that breeds like Pit Bulls, Rottweilers, and German Shepherds can be loyal and dangerous. Proper training and socialization are crucial to preventing aggressive behaviors. Ensure safety by understanding their needs and always supervising interactions. Stay safe, and enjoy your furry friends!
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
1. www.superbugssuperdrugs.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
PLUS ONE INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 21st March 2018, Copthorne Tara Hotel, Kensington, London, UK
@SMIPHARM
#smibugs
SMi present their 20th Annual Conference on…
Superbugs &
Superdrugs
Tackling the scientific, regulatory and economic
challenges to combat anti-microbial resistance
COPTHORNE TARA HOTEL, KENSINGTON, LONDON, UK
The Use of Animal Models in Pre-Clinical Drug Development
08.30 – 12.30
Workshop Leaders:
William Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy
Mark Pulse, Assistant Director, Pre-Clinical Services, UNT System College of Pharmacy
BOOK BY 30TH NOVEMBER AND SAVE £400
BOOK BY 15TH DECEMBER AND SAVE £200
BOOK BY 31ST JANUARY AND SAVE £100
CONFERENCE: 19TH - 20TH
WORKSHOP: 21ST
MAR 2018
Featuring
exclusive
MHRA
keynote
address
NEW FOR 2018:
• Analyse the current status of antimicrobial resistance with
industry led insight into current strategies to tackle AMR
• Hear exclusive case studies from a selection of
pharmaceutical companies on clinical progress
• Learn about regulatory pathways for the registration of new
antimicrobial agents
• Evaluate the latest incentives and funding solutions to spur
drug discovery
• Evaluate the latest novel alternatives to antibiotics currently in
development
CHAIRS FOR 2018:
Richard Bax, Lloyd Czaokewski,
Senior Partner, Director,
TranScrip Partners Chemical Biology Ventures
FEATURED SPEAKERS:
Cara Cassino, Chief Medical Officer and Executive Vice
President of Research and Development, Contrafect
Kathy Talkington, Project Director, Antimicrobial
Resistance, The Pew Charitable Trusts
Jean-Pierre Paccaud, Director of Business Development
and Development Strategy, GARDP, DNDi
John George, Founder/CSO,
Oppilotech
Domingo Gargallo-Viola, Chief Scientific Officer,
ABAC Therapeutics
William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science Center
Larry Sutton, Scientific Founder,
Gladius Pharmaceuticals
ATTENDEE TESTIMONIALS FROM 2017
“Very good & informative meeting”
University Medical Center Utrecht
“Good first experience. Good
to see some presentations on
novel approaches”
Immuno Research Inc
2. *Subject to final confirmation
Superbugs & Superdrugs
Day One | Monday 19th March 2018 www.superbugssuperdrugs.com
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Richard Bax, Senior Partner, Transcrip Partners
FUNDING & INCENTIVES
09.15 OPENING ADDRESS
GARDP: an alternative model to antibiotic drug development
• GARDP is a not-for-profit R&D organisation developing new
treatments to tackle durg-resistant bacterial infections , and
aiming at delivering them in a responsible, sustainable and
accessible manner
• Public-private partnerships contributions to fight AMR:
collaboration and complementarity
• Experimenting alternative business models to deliver innovation
• Current programs and deals will be presented
Dr Jean-Pierre Paccaud, Director of Business Development
and Development Strategy, GARDP, DNDi
09.55 KEYNOTE ADDRESS
Tackling the current lack of incentives for people working in
antimicrobial resistance research and development
• Analysis of the economic issues which affect the research
and development of new antibiotics in the private sector?
• Using ‘risk-sharing’ arrangements between health care payers
and pharmaceutical companies to drive new development
• Which push incentives are the most beneficial and could
similar results be achieved using relevant pull incentives?
• How to ensure that financial incentives for the private sector,
does not prevent drug accessibility to developing countries?
Adrian Towse, Director, Office of Health Economics*
10.35 Morning Coffee
STRATEGIES TO RESURRECT PATHOGEN SENSITIVITY TO ANTIBIOTICS
11.05 Bacterial cybergenetics to resurrect sensitivity to antibiotics in
anti-microbial resistant (AMR) pathogens
• “Nemesis Symbiotics” use programmable RNA-guided DNA
endonuclease gene editing technology to target antibiotic
resistance genes
• A single Symbiotic inactivates members of multiple families
of resistance genes –so resurrecting sensitivity to antibiotics
• Pre-clinical studies show that Transmids, our novel vectors,
deliver Symbiotics to bacteria by phage-coat infection and
subsequently spread by bacterial conjugation
• Symbiotics are biological companion therapeutics to be
used together with well-established antibiotics for both
therapeutic treatment of infection as well as prophylactic
treatment preventing the spread of AMR
Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience
11.45 Using immune modulation alongside antibiotics to counter
multidrug-resistant bacteria
• The antibiotic field can arguably learn from oncology where
immune modulation used alongside chemotherapy has
transformed treatment prospects
• Similarly, to beat resistant bacteria, we need to counter the
way they usurp our immune defenses to evade antibiotics
• Summarising novel ideas on using immune modulation
alongside antibiotics to beat resistant species
• Suggesting that adding a third component could reduce
death rates from sepsis which remain very high even with
use of modern antibiotics
David Brown, Managing Director and Founder,
Alchemy Biomedical Consulting
12.25 Networking Lunch
STRATEGIES TO ASSIST THE DEVELOPMENT OF NEW THERAPEUTICS & DRUGS
KEYNOTE ADDRESS
13.35 SPARKing New Antibiotic Discovery
– the Shared Platform for Antibiotic Research and Knowledge
• The Shared Platform for Antibiotic Research and Knowledge
is a groundbreaking and dynamic information-sharing platform
• Bringing together curated antibiotic discovery data and
cutting-edge analytics to help scientists tackle the scientific
barriers blocking antibiotic discovery
• While the global threat of antibiotic resistance continues
to rise, nearly every antibiotic in use today is based on a
discovery from more than 30 years ago
• SPARK will focus on the unique challenges of finding
and designing antibiotics that can defeat drug-resistant
Gram-negative bacteria, which are among the
hardest-to-treat superbugs
Kathy Talkington, Project Director, Antimicrobial Resistance,
The Pew Charitable Trusts
14.15 Use of the PasNas platform to enable high quality
antibacterial hit finding
• The infectious diseases drug discovery is enormously
inefficient. We can not repeat things over and over again.
What can we do to change this trend?
• Disruptive Innovation to control risk factors, improve
efficiency and ensure delivery
• New paradigms in infectious diseases, from magic bullet
to precision antibacterial agents
Domingo Gargallo-Viola, Chief Scientific Officer,
ABAC Therapeutics
14.55 Afternoon Tea
15.25 Building a detailed computational network model of cell
envelope biogenesis: a systems biology approach to
developing antibacterial drugs (potentiators)
• Model incorporates the synthesis of key components
including LPS, phospholids and peptidoglycan
• The model is used to guide the identification of potentiator
targets– agents that can enhance the activities of existing
antibiotics
• Potentiator programmes derived from model
John George, Founder/CSO, Oppilotech
16.05 Teaching old cephalosporin dogs new mechanistic tricks
against MDR Gram-negative bacteria
• Cephalosporin synthetic scaffolding for new mechanisms
• In vitro activity versus WHO critical priority pathogens
• Comparison to new combination ß-lactams
• In vivo performance
Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
16.45 Novel virulence factors of Acinetobacter baumannii as targets
for antibacterial development
• Over the past 3-4 years, my team has exploited a transposon
mutant library to identify targets required for A. baumannii
virulence in animal models of infection
• Some of these genes/proteins are novel targets on the
surface of the bacterium that we are currently developing
human monoclonal antibodies against
• We have also identified some targets within the bacterium
that could be drug-able
• As we learn and test more, we believe the true strength of
our research is not a single attack against the bacteria, but
rather a combination of multiple drugs/antibodies against
different targets to render the bacteria avirulent and
cleared by the immune system
Daniel Zurawski, Head, Antibacterial Discovery and
Development, Walter Reed Army Institute of Research
(WRAIR)/Bacterial Diseases Branch
17.25 Chairman’s Closing Remarks and Close of Day One
Welcome Letter from our 2018 Chairs
Dear Colleagues,
It is with great pleasure that we welcome you to participate in the
20th Annual Superbugs & Superdrugs Conference taking place on
19th - 20th March 2018, Central London, UK.
We are delighted to chair this annual industry meeting in 2018 again, which
will gather a high level of international experts and project decision makers
to review the successes of 2017 and look to the future of AMR.
This year’s conference has an exciting mix of traditional and alternative
approaches, industry and academia, funders and regulators.
Yours Sincerely,
Richard Bax,
Senior Partner,
TranScrip Partners
Lloyd Czaplewski,
Director,
Chemical Biology
Ventures
Register online at www.superbugssuperdrugs.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion
specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Official Media Partners
3. Superbugs & Superdrugs
www.superbugssuperdrugs.com Day Two | Tuesday 20th March 2018
Supported by
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIES
Want to know how you can get involved? Interested in promoting your services to this market?
Contact – Teri Arri SMi Marketing on +44 (0) 20 7827 6162 or email: tarri@smi-online.co.uk
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Lloyd Czaplewski, Director, Chemical Biology Ventures
OPENING ADDRESS
09.10 Highlights from the Traditional and Alternative Antibacterial
Pipeline
• What new therapies can we anticipate?
• Research challenges
• Are we asking the right questions?
Lloyd Czaplewski, Director, Chemical Biology Ventures
REGULATIONS & CONSIDERATIONS
KEYNOTE ADDRESS
09.50 Regulatory considerations for the registration of new
antibacterial agents
• Ensuring that candidate antibacterial agents with potential
to address an unmet need are evaluated in line with
regulatory guidance
• Options for clinical development programmes
• Importance of the pharmacokinetic-pharmacodynamic
relationship
• Update on recent guidance and planned revisions to EMA
guidance
Mair Powell, Medical Assessor, MHRA
10.30 Morning Coffee
RESEARCH ADVANCES IN ANTIBIOTIC DEVELOPMENT
KEYNOTE ADDRESS
11.00 Iclaprim: a well differentiated, targeted, potent and rapidly
bactericidal antibiotic against multidrug resistant bacteria
• Exploring a novel mechanism of action different from any
other antibiotic currently in development
• Positive clinical outcomes among patients with ABSSSI
and HAP/VAP through optimizing iclaprim’s dose and the
concentration at sites of infection
• Looking into safety data and what lies ahead to achieve
FDA and EMA approval
David Huang, Chief Medical Officer, Motif BioSciences, Inc
11.40 Opening up new opportunities for the treatment of infectious
diseases using nanoformulations
• Nanoformulations formulate drugs into nanoparticles
and can greatly enhance their pharmacokinetic and
pharmacodynamics properties
• Exploring the potential of novel drug nanoformulations to
create new treatments for infections
• Presentation of research and discussion of the potential of
nanoformulations more broadly in infectious disease
David Cook, Chief Scientific Officer,
Blueberry Therapeutics Ltd.
12.20 Networking Lunch
13.20 Challenges in Antimicrobial Evaluation of Novel Therapies
using Animal Models
• Where to start / What model to use
• Dose / Regimen – How to choose
• Test articles with no intrinsic activity
• How to evaluate combination therapy
• What does the data tell us?
William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science Center
NOVEL CANDIDATES AND ALTERNATIVES TO ANTIBIOTICS
KEYNOTE ADDRESS
14.00 Lysins: Alternative Antimicrobials to Improve Clinical
Outcomes Serious Bacterial Infections - CF-301 - A Case Study
• CF-301 demonstrates the hallmark features of lysins,
including: rapid, targeted bacteriolysis, potent synergy with
conventional antibiotics, activity against antibiotic-resistant
strains, low propensity for resistance and remarkable biofilm
eradication, which make lysins attractive therapeutic
candidates for serious bacterial infections.
• In vivo studies with CF-301 signal the therapeutic potential
of lysins boost the efficacy of conventional antibiotics and
combat antimicrobial resistance
• The ongoing CF-301 clinical development program will help
define the place in therapy for ability of lysin therapeutics in
the treatment of serious, invasive,
biofilm-dependent bacterial infections is being evaluated in
clinical development
Cara Cassino, Executive Vice President of Research and
Development and Chief Medical Officer,
Contrafect Corporation
14.40 Afternoon Tea
15.10 C. auris – a difficult to treat, emerging pathogen
• Brief history of C. auris
• How C. auris differs from other candida species
• Experimental models of C. auris
• New potential treatments
Stephen A. Barat, Head of Pre-Clinical Research and Early
Clinical Development, Scynexis
15.50 Amelioration of multi drug resistant infection by antibody
modulation
• Some individuals overproduce antibody that recognises
surface structures on bacteria
• Such antibody interferes with serum killing of the bacterium
• Removal of these antibodies by apharesis restores serum
killing
• Restoration of serum killing is associated with clinical
improvement
Ian R. Henderson, Professor of Microbial Biology,
Director, Institute of Microbiology and Infection,
University of Birmingham
16.30 Chairman’s Closing Remarks and Close of Day Two
4. The Use of Animal Models in Pre-Clinical
Drug Development
Workshop Leaders:
William Weiss, Director, Pre-Clinical Services,
UNT System College of Pharmacy
Mark Pulse, Assistant Director, Pre-Clinical Services,
UNT System College of Pharmacy
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 21st March 2018
08.30 – 12.30
Copthorne Tara Hotel, Kensington, London, UK
Overview of Workshop:
The workshop will provide an overview of the use of animal
models in preclinical drug development. We will focus on the
transition from in vitro activity to in vivo efficacy, the choice of
the right animal model for proof of concept studies, provide
examples of relevant animal models with supportive data and
interpretation of results as they relate to the clinical condition.
Reason to attend:
• To gain an understanding of what animal models can and
cannot provide
• To learn how animal model endpoints relate to clinical
endpoints
• In depth discussion of how models are performed
• Regulations and constraints in the performance of these
models
Programme:
08.30 Registration & Coffee
09.00 Preclinical Animal Models
• Opening remarks and introduction
• History of animal testing
• The general use of animals in research
• Are animal models predictive?
09.30 Experimental Design and Methodology
• How to design the most relevant study for your needs
• Factors that need to be considered – Before, during
and after
• Realistic objectives - What you can and can’t do
• Advantages and Disadvantages
10.30 Morning Coffee
11.00 Animal Models – Examples
• Clinical relevance of current models
• Acute and chronic infection models – From
bacteremia to pneumonia
• GI related infections
• Implanted device infections
• Antifungal testing
• Pharmacokinetics / Pharmacodynamics
12.00 Ethical Use of Animals in Research
• Oversight of animal use in biomedical research
• IACUC – Friend or Foe?
• Governing agencies and regulations for animal
models
• Replace / Refine / Reduce
12.30 Final discussion and close of Workshop
About the Workshop Leaders:
William Weiss Before leading the PreClinical Services
group, Bill was Director of Drug Evaluation at
Cumbre Pharmaceuticals Inc. and a Group Leader
in Infectious Disease Discovery Research at Wyeth
Research (Pfizer), Lederle Laboratories and Schering-Plough
(Merck). His current responsibilities included leading in vitro
and in vivo evaluation of novel test articles from medicinal
synthetic and natural products chemistry. He has worked on
numerous antibacterial programs including the development
of Suprax, Zosyn and Tygacil. His expertise encompasses the
development of animal research models, evaluation of new
and novel therapeutic agents as well as pharmacokinetic /
pharmacodynamic analysis.
Mark Pulse Mark holds a Masters of Science degree
in molecular microbiology and immunology and
his early research at the University of North Texas
Health Science Center primarily focused on bacterial
pathogenesis and pre-clinical drug evaluation within in vivo
models. For the last 12 years he has been directly involved
in the development of multiple in vivo models that have
included GI- and respiratory-associated infectious diseases,
device-associated (biofilm) infections and pharmacokinetic
studies within multiple animal species. He also has experience
with survival surgery in multiple animal models, including USDA
species.
About the organisation:
The Pre-Clinical Services group at the University of North Texas
Health Science Center conducts studies utilizing established
models of both acute and chronic bacterial infections in
several different animal species. UNTHSC Pre-clinical Services
together has over 33 years of pharmaceutical and specialized
biotech experience in the performance of therapeutic
efficacy models and drug discovery / development. The group
uses this experience to guide the drug discovery process,
through protocol design, implementation and analysis for
compound lead selection.
5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and
branding packages, uniquely tailored to complement
your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand
your client base within the context of an independent
discussion specific to your industry. Should you wish to
join the increasing number of companies benefiting
from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
NOVEMBER 2017
Superbugs &
Superdrugs USA
13th - 14th November 2017
New Jersey, USA
Pharmaceutical
Microbiology East Coast
13th - 14th November 2017
New Jersey, USA
Biosimilars North America
15th - 16th November 2017
New Jersey, USA
Lyophilization USA
16th - 17th November 2017
New Jersey, USA
Ophthalmic Drugs
28th - 29th November 2017
London, UK
DECEMBER 2017
Cold Chain Distribution
13th - 14th December 2017
London, UK
JANUARY 2018
Pre-Filled Syringes Europe
17th - 18th January 2018
London, UK
Pharmaceutical
Microbiology
22nd - 23rd January 2018
London, UK
Social Media in the
Pharmaceutical Industry
22nd - 23rd January 2018
London, UK
FEBRUARY 2018
Parallel Trade
6th - 7th February 2018
London, UK
3D Cell Culture
21st - 22nd February 2018
London, UK
RNA Therapeutics
21st - 22nd February 2018
London, UK
MARCH 2018
Superbugs & Superdrugs
19th - 20th March 2018
London, UK
Paediatric Clinical Trials
19th - 20th March 2018
London, UK
Drug Discovery
21st - 22nd March 2018
London, UK
Controlled Release
Delivery
21st - 22nd March 2018
London, UK
APRIL 2018
Antibodies and Antibody
Drug Conjugates
9th - 10th April 2018
London, UK
Adaptive Designs
in Clinical Trials
9th - 10th April 2018
London, UK
Asthma & COPD
11th - 12th April 2018
London, UK
Pre-Filled Syringes
East Coast
11th - 12th April 2018
Boston, MA
MAY 2018
Pharmaceutical Freeze
Drying Technology
9th - 10th May 2018
London, UK
Injectable Drug Delivery
16th - 17th May 2018
London, UK
Pain Therapeutics
21st - 22nd May 2018
London, UK
Highly Potent Active
Pharmaceutical
Ingredients
21st - 22nd May 2018
London, UK
Drug Safety
23rd - 24th May 2018
London, UK
JUNE 2018
Pre-Filled Syringes
West Coast
4th - 5th June 2018
San Diego, CA
Pharmaceutical
Microbiology West Coast
7th - 8th June 2018
San Diego, CA
ADMET
11th - 12th June 2018
London, UK
Molecular Diagnostics
13th - 14th June 2018
London, UK
BioBanking
13th - 14th June 2018
London, UK
SMi Pharmaceutical
Forward Planner
6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-237 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-237
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE CopthorneTaraHotel,Kensington,ScarsdalePlaceKensingtonLondon,W85SR,UK
SUPERBUGS & SUPERDRUGS
Conference: Monday 19th & Tuesday 20th March 2018, Copthorne Tara Hotel, Kensington, London, UK
Workshop: Wednesday 21st March 2018, London, UK
4 WAYS TO REGISTER
www.superbugssuperdrugs.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
□ Book by 30th November to receive £400 off the conference price
□ Book by 15th December to receive £200 off the conference price
□ Book by 31st January to receive £100 off the conference price